The quality of Aseptic products is the most critical challenge in the pharmaceutical industry. It covers those medicinal products that cannot be terminally sterilised, the majority of new injectable IMPs and all gene therapy and ATMPs. In addition, 2019 is a vitally important year as the revised Annex 1 becomes globally implemented and provides a host of challenges for the industry trying to implement it. JPAG has been able to bring together a unique and almost unparalleled group of speakers in a programme that tries to cover the hottest topics in this field.
This symposium is particularly useful as continuing professional development for qualified persons, others involved in the manufacture and quality control of aseptic products in industry and the NHS, as well as those involved in process development.
There will be an opportunity to present posters on the broad subject area of the symposium, subject to acceptance of a submitted abstract.
There will be adequate time after each presentation to discuss case studies and practical implications.
This symposium is particularly useful as continuing professional development for qualified persons, others involved in the manufacture and quality control of aseptic products in industry and the NHS, as well as those involved in process development.
There will be an opportunity to present posters on the broad subject area of the symposium, subject to acceptance of a submitted abstract.
There will be adequate time after each presentation to discuss case studies and practical implications.
